| HOME >> BIOLOGY >> TECHNOLOGY |
financing activities 5,312,735 6,445,974
Effect of exchange rates on cash and cash
equivalents 131,929 3,663
Net increase in cash and cash equivalents 4,095,112 4,151,065
Cash and cash equivalents at beginning of
period 3,763,702 1,563,433
Cash and cash equivalents at end of period $7,858,814 $5,714,498
Supplemental disclosure of cash flow
information:
Cash paid during the period for interest $25,204 $22,011
Cash paid during the period for income taxes 87,900 93,935
Supplemental disclosure of non-cash financing
and investing activities:
Employee retirement savings plan contribution
issued in common shares - 44,385
Property, plant and equipment additions funded
by lessor allowance and classified as deferred
rent - 280,000
Purchase of intellectual property funded by
issuance of stock 4,658,861 -
Non-GAAP Financial Measures. The following table reconciles our
non-GAAP financial measures that exclude non cash charges attributed to
stock options under SFAS 123 (R), and depreciation and amortization
expenses from gross profit, operating expenses and operating loss to our
GAAP financial statements above. The non-GAAP financial measures used by
management and disclosed by us are not a substitute for, or superior to,
financial measures and consolidated financial results calculated in
accordance with GAAP, and you should carefully evaluate our reconciliations
to non-GAAP. We may calculate our non-GAAP financial measures differently
from similarly titled measures used by other companies. Therefore, our
non-GAAP financial measures may not be comparable to those used
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Uroplasty to Host Third Quarter Conference Call on February 11
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |